parabolic2020
21 hours ago
Indeed, most have been affected by reverse splits (RS), myself included. There has been a clear pattern emerging since the beginning of the year. Dr. J has been retweeting every topic he has ever posted, and he has been fulfilling each one. Management has addressed the topic of reverse splits many times, and there will be no reverse split, ever. If you judge them by their actions, you have nothing to worry about. If you judge them by their long-term goals and the facts, our outstanding shares (OS), as illogical as it sounds, may be too small.
The exponential nature of their business model supports this notion. We have only seen the seed multiplication program applied to one seed, and that led to $100 million in assets so far, in just ONE crop cycle (3 months). That was only from Genus Sativa seeds.
Their tissue culture process, which is at the heart of the multiplication program, can be applied to ANY seed. This is a direct quote from management. What will that do? Apply it in parallel processes on MULTIPLE SEED VARIANTS simultaneously?!! Easily billions in asset generation alone per quarter is possible.The model has been proven
Then add in the cannabinoid extraction—what will that do? People also missed that this tech has seemingly exceeded 15x based on lab results Dr. J has posted, which unfortunately fell on deaf ears as well.
The facts and their actions have proven, at least to me, that they will fulfill their objectives without harm to their shareholders.
GLTU.
parabolic2020
2 days ago
In my opinion, there are no scenarios where a spinoff would be necessary. In the long term, I foresee TXTM transitioning away from being a U.S.-based corporation. Given our current structure, there are clear advantages to onboarding into South Africa or continuing to leverage the U.S. Economic Empowerment Agreement with South Africa. This agreement offers access to favorable trade conditions, tax incentives, and emerging markets, which can significantly enhance TXTM’s growth strategy I stated in my post earlier today.
I have repeatedly stated that, due to what I believe to be tortious interference by OTCM, a completed and approved Form 10, along with applications for various exchanges, could already be in place, simply awaiting Dr. J’s approval for public disclosure. This could also explain the lack of reported revenue from the Hemp Order, which, in my opinion, was impacted for legal reasons. Even if this were not the case, there is nothing currently holding the company back. Full stop.
For a direct path to the NYSE, TXTM can demonstrate expected revenue that was impeded by OTCM’s interference and qualify with this anticipated revenue in conjunction with our $100 million in assets. The company would only need to provide proof of deliverability and production capacity to meet the necessary requirements to fulfill the Hemp Contract.
With regard to the OTCQX, we have been compelled to meet higher-tier requirements to remove the Caveat Emptor (CE) designation, which involved audits and additional injections, actions that may potentially violate FTC regulations. However, with completed PCAOB audits and a sponsor, the Form 10 could qualify us for listing on all U.S. exchanges.
As for the JSE, our auditor is IFRS compliant and is approved for submission to the JSE as a member of the Independent Regulatory Board for Auditors (IRBA). These IFRS audits may already qualify us for listing on the JSE, given that we now meet all the necessary requirements. A close examination of our GAAP filings clearly shows a dual listing in progress, as our assets are reported in both USD and ZAR (RAND).
While the SEC requires PCAOB audits under Sarbanes-Oxley for U.S.-based companies, our auditor, as previously noted, is a former director at PricewaterhouseCoopers. She could submit the audits to a firm like Pricewaterhouse, and under the AS 1204-1205 standard, they would likely be accepted. Why this has been such a large point of contention, I am unsure—it seems straightforward and easily achievable to me.
IMO there are no legal or listing criteria that I see preventing TXTM from meeting the requirements for any exchange globally.
GLTU
parabolic2020
2 days ago
TXTM's Emerging Business Model:
A hybrid Holding-Banking-Acquisition-Distribution-Technology Conglomerate
What makes TXTM truly unique is how it’s been able to skip the toughest, most expensive stages of building a business. Thanks to the existing infrastructure provided by Leeds and its network of farms, TXTM didn’t have to start from scratch. This gave the company a head start, allowing it to focus on scaling and setting itself up to fully benefit from the profits.
Before dismissing the comparison to BlackRock and Berkshire Hathaway, take a closer look at their business models and compare them to what Dr. J and TXTM have already revealed. The parallels and the improvements TXTM has made are key to understanding why this company is different.
The real strength of TXTM lies in the scale of its operations, supported by Leeds and the infrastructure already in place, combined with the Human Capital of Dr. J. His experience give TXTM an edge in innovation and growth, making the company a real future contender in the market.
Another key factor is TXTM’s proprietary extraction technology. This technology gives the company a serious advantage, with higher retention rates and greater potency compared to its competitors. It’s not just efficient—it’s also cost-effective and likely far exceeding 15X initial target bio availability, which means TXTM is set to stand out in the market while boosting its profitability.
It’s time to really understand what TXTM is all about and how its business model works. Dr. J has taken inspiration from the best features of two industry giants—BlackRock and Berkshire Hathaway—and improved on them to create something even stronger for TXTM.
Rather than focusing on the size of BlackRock or Berkshire Hathaway, it's more important to examine the foundation of their business models and the challenges they face.
BlackRock’s approach, much like TXTM’s Bank model, revolves around managing a large portfolio of assets such as stocks, bonds, and real estate, all while incorporating advanced technology like blockchain. However, BlackRock's assets can be volatile. TXTM aims to improve on this by launching its own ETF—referred to as the "investor-managed fund" in tweets from 2022. By replacing volatile assets with stable, real-world ones and adding blockchain technology for transparency, TXTM reduces the risks while keeping the advantages of the model intact.
On the other hand, Berkshire Hathaway has built its success by owning stakes in a variety of businesses but letting them run independently. This has worked well for them, but their recent shift to converting stock holdings into cash shows a vulnerability during downturns. TXTM takes a different approach—while it will diversify like Berkshire, it will likely also keep direct control over its acquisitions, ensuring more oversight and flexibility to adapt quickly as it preforms the function of a holding company ( which it already is).
What really sets TXTM apart is Dr. J’s focus on innovation. These innovations, due to their scale, have the potential to become independent companies or be fully integrated into TXTM’s operations—just like the seed multiplication program. This kind of flexibility allows TXTM to grow both through acquisitions and by developing its own breakthroughs.
By blending acquisitions with internal innovations, TXTM has built a unique business model that combines the best of BlackRock’s financial expertise and Berkshire Hathaway’s diversification. At the same time, it’s pushing the boundaries with cutting-edge technology and scalable solutions.
The most recent "Tweets" hint at future developments and direction:
Scaling Operations: TXTM plans to expand its seed multiplication program by increasing partnerships and scaling production to meet the global demand for high-quality hemp seeds.
Global Market Penetration: The company aims to enter key international markets, particularly in Europe, Latin America, and Asia, forming strategic partnerships and distribution agreements.
Technological Application Beyond Hemp: TXTM is exploring how its patented cannabinoid extraction technology can be used on other crops, allowing the company to diversify its offerings and enter new agricultural sectors.
Metaverse Integration: TXTM is at the forefront of digital innovation, integrating its operations into the metaverse. By tokenizing book assets, customers can own fractional shares of production cycles, providing both digital engagement and new revenue opportunities.
Potential Uplisting: As part of its long-term strategy, TXTM is preparing for potential uplisting on major exchanges such as the NYSE/JSE, enabling access to capital markets for continued growth in both traditional and digital industries.
This is who we are and what we’re evolving into. $100 Million and counting...
GLTU